ProShare Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

ProShare Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Buy	+7,070	New	+$367K	﹤0.01%	1155
2025 Q2	–	Sell	-10,225	Closed	-$227K	–	2134
2025 Q1	$227K	Sell	10,225 -2,582	-20%	-$53.1K	﹤0.01%	1602
2024 Q4	$253K	Buy	12,807 +3,357	+36%	+$76.6K	﹤0.01%	1759
2024 Q3	$236K	Buy	+9,450	New	+$230K	﹤0.01%	1631
2022 Q1	–	Sell	-11,143	Closed	-$131K	–	2255
2021 Q4	$131K	Buy	11,143 +433	+4%	+$5.32K	﹤0.01%	2156
2021 Q3	$122K	Sell	10,710 -2,664	-20%	-$34.7K	﹤0.01%	1884
2021 Q2	$186K	Buy	13,374 +1,814	+16%	+$27.6K	﹤0.01%	2166
2021 Q1	$214K	Buy	11,560 +754	+7%	+$15.4K	﹤0.01%	2001
2020 Q4	$191K	Buy	+10,806	New	+$190K	﹤0.01%	1858

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

ProShare Advisors's KNSA Position: Q2 2026 in Review

ProShare Advisors opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 7,070 shares worth $452K. The stake represents ﹤0.01% of the portfolio and ranks #1155 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in KNSA as recently as Q1 2025.

ProShare Advisors first reported a position in KNSA in Q4 2020 and has held it in 9 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

ProShare Advisors held 7,070 shares of Kiniksa Pharmaceuticals worth $452K as of Q2 2026.
Kiniksa Pharmaceuticals was a new ProShare Advisors position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1155 holding.
ProShare Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.